bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data from MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Authors: Guo Robin , Offin Michael , Brannon A. Rose , Chang Jason , Chow Andrew , Delasos Lukas , Girshman Jeffrey , Wilkins Olivia , McCarthy Caroline G. , Makhnin Alex , Falcon Christina , Scott Kerry , Tian Yuan , Cecchi Fabiola , Hembrough Todd , Alex Deepu , Shen Ronglai , Benayed Ryma , Li Bob T. , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Rekhtman Natasha , Paik Paul , Zehir Ahmet , Drilon Alexander
Published: April 2023

Supplementary Figures S1-S6, Table S1-S3, and eMethods
Supplementary Figure S3 from Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Authors: Guo Jimmy A. , Hoffman Hannah I. , Shroff Stuti G. , Chen Peter , Hwang Peter G. , Kim Daniel Y. , Kim Daniel W. , Cheng Stephanie W. , Zhao Daniel , Mahal Brandon A. , Alshalalfa Mohammed , Niemierko Andrzej , Wo Jennifer Y. , Loeffler Jay S. , Fernandez-del Castillo Carlos , Jacks Tyler , Aguirre Andrew J. , Hong Theodore S. , Mino-Kenudson Mari , Hwang William L.
Published: April 2023

Supplementary Figure S3
Table S1 from Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Authors: Guerini-Rocco Elena , Gray Kathryn P. , Fumagalli Caterina , Reforgiato Marta Rita , Leone Isabella , Rafaniello Raviele Paola , Munzone Elisabetta , Kammler Roswitha , Neven Patrick , Hitre Erika , Jerusalem Guy , Simoncini Edda , Gombos Andrea , Deleu Ines , Karlsson Per , Aebi Stefan , Chirgwin Jacquie , Di Lauro Vincenzo , Thompson Alastair , Graas Marie-Pascale , Barber Matthew , Fontaine Christel , Loibl Sibylle , Gavilá Joaquín , Kuroi Katsumasa , Müller Bettina , O’Reilly Seamus , Di Leo Angelo , Goldhirsch Aron , Viale Giuseppe , Barberis Massimo , Regan Meredith M. , Colleoni Marco
Published: April 2023

Clinico-pathologic characteristics of patients according to NGS results (success/failure).
Figure S1 from Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Authors: Guerini-Rocco Elena , Gray Kathryn P. , Fumagalli Caterina , Reforgiato Marta Rita , Leone Isabella , Rafaniello Raviele Paola , Munzone Elisabetta , Kammler Roswitha , Neven Patrick , Hitre Erika , Jerusalem Guy , Simoncini Edda , Gombos Andrea , Deleu Ines , Karlsson Per , Aebi Stefan , Chirgwin Jacquie , Di Lauro Vincenzo , Thompson Alastair , Graas Marie-Pascale , Barber Matthew , Fontaine Christel , Loibl Sibylle , Gavilá Joaquín , Kuroi Katsumasa , Müller Bettina , O’Reilly Seamus , Di Leo Angelo , Goldhirsch Aron , Viale Giuseppe , Barberis Massimo , Regan Meredith M. , Colleoni Marco
Published: April 2023

Representative image of FISH analysis for FGFR1 gene on chromosome 8p12 (green) and centromeric region of chromosome 8 (red signal) showing FGFR1 copy number gain/amplification.
Supplementary Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
Authors: Serebrenik Artur A. , Argyris Prokopios P. , Jarvis Matthew C. , Brown William L. , Bazzaro Martina , Vogel Rachel I. , Erickson Britt K. , Lee Sun-Hee , Goergen Krista M. , Maurer Matthew J. , Heinzen Ethan P. , Oberg Ann L. , Huang Yajue , Hou Xiaonan , Weroha S. John , Kaufmann Scott H. , Harris Reuben S.
Published: April 2023

Supplementary Methods, Tables, and Figures
Supplementary Figure 5 from Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice
Authors: Zhang Ian Y. , Zhou Hui , Liu Huili , Zhang Leying , Gao Hang , Liu Shunan , Song Yanyan , Alizadeh Darya , Yin Hongwei Holly , Pillai Raju , Badie Behnam
Published: April 2023

Supplementary Figure 5
Supplementary Figure 4 from Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice
Authors: Zhang Ian Y. , Zhou Hui , Liu Huili , Zhang Leying , Gao Hang , Liu Shunan , Song Yanyan , Alizadeh Darya , Yin Hongwei Holly , Pillai Raju , Badie Behnam
Published: April 2023

Supplementary Figure 4
Supplementary tables from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Authors: Rivas-Delgado Alfredo , Nadeu Ferran , Enjuanes Anna , Casanueva-Eliceiry Sebastián , Mozas Pablo , Magnano Laura , Castrejón de Anta Natalia , Rovira Jordina , Dlouhy Ivan , Martín Silvia , Osuna Miguel , Rodríguez Sonia , Simó Marc , Pinyol Magda , Baumann Tycho , Beà Silvia , Balagué Olga , Delgado Julio , Villamor Neus , Setoain Xavier , Campo Elías , Giné Eva , López-Guillermo Armando
Published: April 2023

Supplementary tables S1 to S6
Supplemental Material from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Authors: Rivas-Delgado Alfredo , Nadeu Ferran , Enjuanes Anna , Casanueva-Eliceiry Sebastián , Mozas Pablo , Magnano Laura , Castrejón de Anta Natalia , Rovira Jordina , Dlouhy Ivan , Martín Silvia , Osuna Miguel , Rodríguez Sonia , Simó Marc , Pinyol Magda , Baumann Tycho , Beà Silvia , Balagué Olga , Delgado Julio , Villamor Neus , Setoain Xavier , Campo Elías , Giné Eva , López-Guillermo Armando
Published: April 2023

Suppplementary Methods and Figures
Supplementary Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Authors: Yang Yuan , Yang Howard H. , Tang Binwu , Wu Alex Man Lai , Flanders Kathleen C. , Moshkovich Nellie , Weinberg Douglas S. , Welsh Michael A. , Weng Jia , Ochoa Humberto J. , Hu Tiffany Y. , Herrmann Michelle A. , Chen Jinqiu , Edmondson Elijah F. , Simpson R. Mark , Liu Fang , Liu Huaitian , Lee Maxwell P. , Wakefield Lalage M.
Published: April 2023

Supplementary Table S1
Supplementary Materials and Methods from EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
Authors: Wu Shaofang , Gao Feng , Zheng Siyuan , Zhang Chen , Martinez-Ledesma Emmanuel , Ezhilarasan Ravesanker , Ding Jie , Li Xiaolong , Feng Ningping , Multani Asha , Sulman Erik P. , Verhaak Roel G. , de Groot John F. , Heffernan Tim P. , Yung W.K. Alfred , Koul Dimpy
Published: April 2023

Supplementary Materials and Methods
Supplementary Figures and legends from EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
Authors: Wu Shaofang , Gao Feng , Zheng Siyuan , Zhang Chen , Martinez-Ledesma Emmanuel , Ezhilarasan Ravesanker , Ding Jie , Li Xiaolong , Feng Ningping , Multani Asha , Sulman Erik P. , Verhaak Roel G. , de Groot John F. , Heffernan Tim P. , Yung W.K. Alfred , Koul Dimpy
Published: April 2023

Supplemental Figures and legends for Figure S1-S8
Supplementary Data from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
Authors: Ogura Koichi , Somwar Romel , Hmeljak Julija , Magnan Heather , Benayed Ryma , Momeni Boroujeni Amir , Bowman Anita S. , Mattar Marissa S. , Khodos Inna , de Stanchina Elisa , Jungbluth Achim , Asher Marina , Odintsov Igor , Hartono Alifiani B. , LaQuaglia Michael P. , Slotkin Emily , Pratilas Christine A. , Lee Sean Bong , Spraggon Lee , Ladanyi Marc
Published: April 2023

Supplementary Table 2
Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
Authors: LeBlanc Amy K. , Mazcko Christina N. , Cherukuri Aswini , Berger Erika P. , Kisseberth William C. , Brown Megan E. , Lana Susan E. , Weishaar Kristen , Flesner Brian K. , Bryan Jeffrey N. , Vail David M. , Burton Jenna H. , Willcox Jennifer L. , Mutsaers Anthony J. , Woods J. Paul , Northrup Nicole C. , Saba Corey , Curran Kaitlin M. , Leeper Haley , Wilson-Robles Heather , Wustefeld-Janssens Brandan G. , Lindley Stephanie , Smith Annette N. , Dervisis Nikolaos , Klahn Shawna , Higginbotham Mary Lynn , Wouda Raelene M. , Krick Erika , Mahoney Jennifer A. , London Cheryl A. , Barber Lisa G. , Balkman Cheryl E. , McCleary-Wheeler Angela L. , Suter Steven E. , Martin Olya , Borgatti Antonella , Burgess Kristine , Childress Michael O. , Fidel Janean L. , Allstadt Sara D. , Gustafson Daniel L. , Selmic Laura E. , Khanna Chand , Fan Timothy M.
Published: April 2023

Supplementary Fig. 2 shows the walk-in pharmacokinetics, both measured results and simulated values, for dogs treated with oral sirolimus in preparation for the definitive adjuvant trial.
Supplementary Tables S1-S13 from Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer
Authors: Li Christopher I. , Zhang Yuping , Cieślik Marcin , Wu Yi-Mi , Xiao Lanbo , Cobain Erin , Tang Mei-Tzu C. , Cao Xuhong , Porter Peggy , Guenthoer Jamie , Robinson Dan R. , Chinnaiyan Arul M.
Published: April 2023

Excel file containing Tables S1 through S13
Figure S2 from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
Authors: Ogura Koichi , Somwar Romel , Hmeljak Julija , Magnan Heather , Benayed Ryma , Momeni Boroujeni Amir , Bowman Anita S. , Mattar Marissa S. , Khodos Inna , de Stanchina Elisa , Jungbluth Achim , Asher Marina , Odintsov Igor , Hartono Alifiani B. , LaQuaglia Michael P. , Slotkin Emily , Pratilas Christine A. , Lee Sean Bong , Spraggon Lee , Ladanyi Marc
Published: April 2023

Supplementary Figure 2. Characterization of SK DSRCT2.
Supplementary Figures S1-S10 from Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer
Authors: Li Christopher I. , Zhang Yuping , Cieślik Marcin , Wu Yi-Mi , Xiao Lanbo , Cobain Erin , Tang Mei-Tzu C. , Cao Xuhong , Porter Peggy , Guenthoer Jamie , Robinson Dan R. , Chinnaiyan Arul M.
Published: April 2023

Supplementary Figures S1 through S10
Supplementary Data from Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma
Authors: Marostica Eliana , Barber Rebecca , Denize Thomas , Kohane Isaac S. , Signoretti Sabina , Golden Jeffrey A. , Yu Kun-Hsing
Published: April 2023

Supplementary legends
Figure S3 from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Authors: Kazmi Farasat , Nicum Shibani , Roux Rene L. , Spiers Laura , Gnanaranjan Chat , Sukumaran Ajithkumar , Gabra Hani , Ghazaly Essam , McCracken Nigel W. , Harrison David J. , Blagden Sarah P.
Published: April 2023

PC PVC of base PK model based on median parameters
Table S1 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Authors: Hellmann Matthew D. , Nabet Barzin Y. , Rizvi Hira , Chaudhuri Aadel A. , Wells Daniel K. , Dunphy Mark P.S. , Chabon Jacob J. , Liu Chih Long , Hui Angela B. , Arbour Kathryn C. , Luo Jia , Preeshagul Isabel R. , Moding Everett J. , Almanza Diego , Bonilla Rene F. , Sauter Jennifer L. , Choi Hyejin , Tenet Megan , Abu-Akeel Mohsen , Plodkowski Andrew J. , Perez Johnston Rocio , Yoo Christopher H. , Ko Ryan B. , Stehr Henning , Gojenola Linda , Wakelee Heather A. , Padda Sukhmani K. , Neal Joel W. , Chaft Jamie E. , Kris Mark G. , Rudin Charles M. , Merghoub Taha , Li Bob T. , Alizadeh Ash A. , Diehn Maximilian
Published: April 2023

Table S1 shows summary patient demographics, pathologic features, and treatment details
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Authors: Hellmann Matthew D. , Nabet Barzin Y. , Rizvi Hira , Chaudhuri Aadel A. , Wells Daniel K. , Dunphy Mark P.S. , Chabon Jacob J. , Liu Chih Long , Hui Angela B. , Arbour Kathryn C. , Luo Jia , Preeshagul Isabel R. , Moding Everett J. , Almanza Diego , Bonilla Rene F. , Sauter Jennifer L. , Choi Hyejin , Tenet Megan , Abu-Akeel Mohsen , Plodkowski Andrew J. , Perez Johnston Rocio , Yoo Christopher H. , Ko Ryan B. , Stehr Henning , Gojenola Linda , Wakelee Heather A. , Padda Sukhmani K. , Neal Joel W. , Chaft Jamie E. , Kris Mark G. , Rudin Charles M. , Merghoub Taha , Li Bob T. , Alizadeh Ash A. , Diehn Maximilian
Published: April 2023

Supplementary Figures related to Figures 1, 2, 3, and 4.
Table S4 from Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Authors: Yu Helena A. , Paz-Ares Luis G. , Yang James Chih-Hsin , Lee Ki Hyeong , Garrido Pilar , Park Keunchil , Kim Joo-Hang , Lee Dae Ho , Mao Huzhang , Wijayawardana Sameera R. , Gao Ling , Hozak Rebecca R. , Chao Bo H. , Planchard David
Published: April 2023

Summary of Death and Adverse Events of Special Interest
Table S3 from Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Authors: Yu Helena A. , Paz-Ares Luis G. , Yang James Chih-Hsin , Lee Ki Hyeong , Garrido Pilar , Park Keunchil , Kim Joo-Hang , Lee Dae Ho , Mao Huzhang , Wijayawardana Sameera R. , Gao Ling , Hozak Rebecca R. , Chao Bo H. , Planchard David
Published: April 2023

Summary of Serious Adverse Events by System Organ Class and Preferred Term
Supplementary Data 4 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Authors: Hackeng Wenzel M. , Dreijerink Koen M.A. , de Leng Wendy W.J. , Morsink Folkert H.M. , Valk Gerlof D. , Vriens Menno R. , Offerhaus G. Johan A. , Geisenberger Christoph , Brosens Lodewijk A.A.
Published: April 2023

NEN-ID local and external cohort scores
Table S1 from Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Authors: Yu Helena A. , Paz-Ares Luis G. , Yang James Chih-Hsin , Lee Ki Hyeong , Garrido Pilar , Park Keunchil , Kim Joo-Hang , Lee Dae Ho , Mao Huzhang , Wijayawardana Sameera R. , Gao Ling , Hozak Rebecca R. , Chao Bo H. , Planchard David
Published: April 2023

Dose Adjustments
Supplemental Table 1 from Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors
Authors: Vidula Neelima , Rich Thereasa A. , Sartor Oliver , Yen Jennifer , Hardin Aaron , Nance Tracy , Lilly Michael B. , Nezami Mohammad Amin , Patel Sandip P. , Carneiro Benedito A. , Fan Alice C. , Brufsky Adam M. , Parker Barbara A. , Bridges Benjamin B. , Agarwal Neeraj , Maughan Benjamin L. , Raymond Victoria M. , Fairclough Stephen R. , Lanman Richard B. , Bardia Aditya , Cristofanilli Massimo
Published: April 2023

Supplemental Table 1
Sensitivity and Specificity Table and ROC Curve from Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
Authors: Lucci Anthony , Hall Carolyn S. , Patel Sapna P. , Narendran Boomadevi , Bauldry Jessica B. , Royal Richard E. , Karhade Mandar , Upshaw Joshua R. , Wargo Jennifer A. , Glitza Isabella C. , Wong Michael K.K. , Amaria Rodabe N. , Tawbi Hussein A. , Diab Adi , Davies Michael A. , Gershenwald Jeffrey E. , Lee Jeffrey E. , Hwu Patrick , Ross Merrick I.
Published: April 2023

Sensitivity and Specificity CTC Detection Table and ROC Curve
Supplemental Figure 2 from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Authors: Alewine Christine , Ahmad Mehwish , Peer Cody J. , Hu Zishuo I. , Lee Min-Jung , Yuno Akira , Kindrick Jessica D. , Thomas Anish , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Hassan Raffit , Pastan Ira
Published: April 2023

Adverse events attributed to nab-paclitaxel
Supplemental Figure 1 from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Authors: Alewine Christine , Ahmad Mehwish , Peer Cody J. , Hu Zishuo I. , Lee Min-Jung , Yuno Akira , Kindrick Jessica D. , Thomas Anish , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Hassan Raffit , Pastan Ira
Published: April 2023

Order of study arm enrollment is displayed graphically
Supplemental Table 2 from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Authors: Xie Hao , Mahoney Douglas W. , Foote Patrick H. , Burger Kelli N. , Doering Karen A. , Taylor William R. , Then Sara S. , Cao Xiaoming , McGlinch Maria , Berger Calise K. , Wu Tsung-Teh , Hubbard Joleen M. , Allawi Hatim T. , Kaiser Michael W. , Lidgard Graham P. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Table 2. Intraclass correlation coefficients (with 95% confidence intervals) between primary colorectal cancer and metastatic disease, either synchronous or metachronous indicate concordance of methylated DNA marker levels in total DNA extracted from these tissues
Figure S3 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Authors: Sharma Priyanka , Kimler Bruce F. , O'Dea Anne , Nye Lauren , Wang Yen Y. , Yoder Rachel , Staley Joshua M. , Prochaska Lindsey , Wagner Jamie , Amin Amanda L. , Larson Kelsey , Balanoff Christa , Elia Manana , Crane Gregory , Madhusudhana Sheshadri , Hoffmann Marc , Sheehan Maureen , Rodriguez Roberto , Finke Karissa , Shah Rajvi , Satelli Deepti , Shrestha Anuj , Beck Larry , McKittrick Richard , Pluenneke Robert , Raja Vinay , Beeki Venkatadri , Corum Larry , Heldstab Jaimie , LaFaver Stephanie , Prager Micki , Phadnis Milind , Mudaranthakam Dinesh Pal , Jensen Roy A. , Godwin Andrew K. , Salgado Roberto , Mehta Kathan , Khan Qamar
Published: April 2023

Median stromal tumor-infiltrating lymphocytes
Supplemental Table 1 from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Authors: Xie Hao , Mahoney Douglas W. , Foote Patrick H. , Burger Kelli N. , Doering Karen A. , Taylor William R. , Then Sara S. , Cao Xiaoming , McGlinch Maria , Berger Calise K. , Wu Tsung-Teh , Hubbard Joleen M. , Allawi Hatim T. , Kaiser Michael W. , Lidgard Graham P. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Table 1 Baseline characteristics of patients in Primary and Metastatic Tissue MDM Concordance Study
Supplemental Figure 4 from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Authors: Xie Hao , Mahoney Douglas W. , Foote Patrick H. , Burger Kelli N. , Doering Karen A. , Taylor William R. , Then Sara S. , Cao Xiaoming , McGlinch Maria , Berger Calise K. , Wu Tsung-Teh , Hubbard Joleen M. , Allawi Hatim T. , Kaiser Michael W. , Lidgard Graham P. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 4: Carcinoembryonic antigen (CEA) levels in nanograms per milliliter assayed from 10 microliters serum in the Early Detection experiment are 1.5 times higher than values assayed from 10 microliters of plasma in the Surveillance experiment. Blue reference line marks median values in serum for normal control patients and orange line marks median serum value for stage IV colorectal cancer cases. CEA values in the surveillance samples were re-scaled to allow application of the model derived in the Early Detection analysis to the Surveillance data set.
Supplementary Tables from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Authors: Paik Paul K. , Kim Rachel K. , Ahn Linda , Plodkowski Andrew J. , Ni Ai , Donoghue Mark T.A. , Jonsson Philip , Villalona-Calero Miguel , Ng Kenneth , McFarland Daniel , Fiore John J. , Iqbal Afsheen , Eng Juliana , Kris Mark G. , Rudin Charles M.
Published: April 2023

Tables S1-S6
Supplemental Figure 2 from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Authors: Xie Hao , Mahoney Douglas W. , Foote Patrick H. , Burger Kelli N. , Doering Karen A. , Taylor William R. , Then Sara S. , Cao Xiaoming , McGlinch Maria , Berger Calise K. , Wu Tsung-Teh , Hubbard Joleen M. , Allawi Hatim T. , Kaiser Michael W. , Lidgard Graham P. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 2: The importance of individual MDMs and CEA in contribution to the performance of random forest model in classification of early CRC from healthy control in MDM Plasma CRC Early Primary Detection Study. MDM: methylated DNA marker; CEA: carcinoembryonic antigen; CRC: colorectal cancer.
Figure S2 from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Authors: Paik Paul K. , Kim Rachel K. , Ahn Linda , Plodkowski Andrew J. , Ni Ai , Donoghue Mark T.A. , Jonsson Philip , Villalona-Calero Miguel , Ng Kenneth , McFarland Daniel , Fiore John J. , Iqbal Afsheen , Eng Juliana , Kris Mark G. , Rudin Charles M.
Published: April 2023

Oncoprint of all somatic alterations detected on MSK-IMPACT
Supplementary Figure S2 from Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Authors: Hollebecque Antoine , Salvagni Stefania , Plummer Ruth , Isambert Nicolas , Niccoli Patricia , Capdevila Jaume , Curigliano Giuseppe , Moreno Victor , Martin-Romano Patricia , Baudin Eric , Arias Marina , Mora Sheila , de Alvaro Juan , Di Martino Jorge , Parra-Palau Josep L. , Sánchez-Pérez Tania , Aronchik Ida , Filvaroff Ellen H. , Lamba Manisha , Nikolova Zariana , de Bono Johann S.
Published: April 2023

Supplementary Figure S2. CC-90011 Dose Response in a Kasumi-1 Cell Line Model of Acute Myeloid Leukemia (A) and a Normal Human Fibroblast Cell Line Model (B). CellTiter 96® aqueous cell proliferation assay results shown.
Figure S3 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo
Authors: Anastasiadou Eleni , Seto Anita G. , Beatty Xuan , Hermreck Melanie , Gilles Maud-Emmanuelle , Stroopinsky Dina , Pinter-Brown Lauren C. , Pestano Linda , Marchese Cinzia , Avigan David , Trivedi Pankaj , Escolar Diana M. , Jackson Aimee L. , Slack Frank J.
Published: April 2023

Supplementary figure S3
Supplementary Methods from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

Supplementary Methods
Table S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Authors: Foltz Jennifer A. , Hess Brian T. , Bachanova Veronika , Bartlett Nancy L. , Berrien-Elliott Melissa M. , McClain Ethan , Becker-Hapak Michelle , Foster Mark , Schappe Timothy , Kahl Brad , Mehta-Shah Neha , Cashen Amanda F. , Marin Nancy D. , McDaniels Kristen , Moreno Chaz , Mosior Matthew , Gao Feng , Griffith Obi L. , Griffith Malachi , Wagner Julia A. , Epperla Narendranath , Rock Amy D. , Lee John , Petti Allegra A. , Soon-Shiong Patrick , Fehniger Todd A.
Published: April 2023

Mass Cytometry Antibody Panel
Table S4 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Authors: Ai Xinghao , Cui Jiuwei , Zhang Jiexia , Chen Rongrong , Lin Wen , Xie Congying , Liu Anwen , Zhang Junping , Yang Weihua , Hu Xiaohua , Zhao Qiong , Rao Chuangzhou , Zang Yuan-Sheng , Ning Ruiling , Li Pansong , Chang Lianpeng , Yi Xin , Lu Shun
Published: April 2023

Other driver mutations in 22 discordant cases.
Table S3 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Authors: Ai Xinghao , Cui Jiuwei , Zhang Jiexia , Chen Rongrong , Lin Wen , Xie Congying , Liu Anwen , Zhang Junping , Yang Weihua , Hu Xiaohua , Zhao Qiong , Rao Chuangzhou , Zang Yuan-Sheng , Ning Ruiling , Li Pansong , Chang Lianpeng , Yi Xin , Lu Shun
Published: April 2023

Baseline characteristics, EGFR mutation and EGFR-TKIs of patients who were separated into EGFR dominant or nondominant groups.
Supplementary Methods from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Authors: Rosen Ezra Y. , Johnson Melissa L. , Clifford Sarah E. , Somwar Romel , Kherani Jennifer F. , Son Jieun , Bertram Arrien A. , Davare Monika A. , Gladstone Eric , Ivanova Elena V. , Henry Dahlia N. , Kelley Elaine M. , Lin Mika , Milan Marina S.D. , Nair Binoj C. , Olek Elizabeth A. , Scanlon Jenna E. , Vojnic Morana , Ebata Kevin , Hechtman Jaclyn F. , Li Bob T. , Sholl Lynette M. , Taylor Barry S. , Ladanyi Marc , Jänne Pasi A. , Rothenberg S. Michael , Drilon Alexander , Oxnard Geoffrey R.
Published: April 2023

Supplementary Methods
Supplementary Figure S1 from Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases
Authors: Angus Lindsay , Deger Teoman , Jager Agnes , Martens John W.M. , de Weerd Vanja , van Heuvel Irene , van den Bent Martin J. , Sillevis Smitt Peter A.E. , Kros Johan M. , Bindels Eric M.J. , Heitzer Ellen , Sleijfer Stefan , Jongen Joost L.M. , Wilting Saskia M.
Published: April 2023

The delta genome-wide Z score increases with lower numbers of mapped reads and diverges for controls (healthy donor liquor) and cases (patient liquor) below 90,000 reads. In addition, a higher standard deviation over the samples is observed below 90,000 reads.
Supplementary Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
Authors: Chalfin Heather J. , Pramparo Tiziano , Mortazavi Amir , Niglio Scot A. , Schonhoft Joseph D. , Jendrisak Adam , Chu Yen-Lin , Richardson Robin , Krupa Rachel , Anderson Amanda K.L. , Wang Yipeng , Dittamore Ryan , Pal Sumanta K. , Lara Primo N. , Stein Mark N. , Quinn David I. , Steinberg Seth M. , Cordes Lisa M. , Ley Lisa , Mallek Marissa , Sierra Ortiz Olena , Costello Rene , Cadena Jacqueline , Diaz Carlos , Gulley James L. , Dahut William L. , Streicher Howard , Wright John J. , Trepel Jane B. , Bottaro Donald P. , Apolo Andrea B.
Published: April 2023

Supplementary Data
Supplementary Table S3 from Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Authors: Vidula Neelima , Niemierko Andrzej , Malvarosa Giuliana , Yuen Megan , Lennerz Jochen , Iafrate A. John , Wander Seth A. , Spring Laura , Juric Dejan , Isakoff Steven , Younger Jerry , Moy Beverly , Ellisen Leif W. , Bardia Aditya
Published: April 2023

Supplemental Table S3. Actionable mutations found in cfDNA and tumor tissue genotyping in 12 patients who went on to receive matched therapy after having both forms of testing.
Figure S3 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

Kaplan-Meier plots of probability of overall survival in patients with advanced PDAC receiving first-line FOLFIRINOX (A) or nab-paclitaxel/gemcitabine (B) or patients with GC/EGJC receiving an oxaliplatin-containing regimen (C). A) The median OS in the Increased Benefit cohort is 10.1 months (90%) longer than the median OS in the Decreased Benefit cohort (HR = 0.478, 95% CI: 0.289-0.792, log-rank p = 0.003). B) The median OS in the Increased Benefit cohort is one month (11%) longer than the median OS in the Decreased Benefit cohort (HR = 0.958, 95% CI: 0.658-1.395, log-rank p = 0.823). C) The median OS in the Increased Benefit cohort is 5.1 months (58%) longer than the median OS in the Decreased Benefit cohort (HR = 0.437, 95% CI: 0.250-0.763, log-rank p = 0.003).
Figure S1 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

A) Correlation of TTNT and PFS of cases in the TRIBE2 trial. B) Distribution of mCRC RWE TNTs compared with PFS from the FOLFOX and FOLFOXIRI arms of the TRIBE2 trial.
Supplementary Materials II: Supplementary Figures S1-40 from Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model
Authors: Andreassen Maren M. Sjaastad , Rodríguez-Soto Ana E. , Conlin Christopher C. , Vidić Igor , Seibert Tyler M. , Wallace Anne M. , Zare Somaye , Kuperman Joshua , Abudu Boya , Ahn Grace S. , Hahn Michael , Jerome Neil P. , Østlie Agnes , Bathen Tone F. , Ojeda-Fournier Haydee , Goa Pål Erik , Rakow-Penner Rebecca , Dale Anders M.
Published: April 2023

Probability density colormaps for the three-component model given C1 and C2 for all voxels per patient for (A.) cancer (cancer ROI) and (B.) healthy breast tissue (control ROI).
Supplementary Data from Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Authors: Lim Bora , Potter David A. , Salkeni Mohamad A. , Silverman Paula , Haddad Tufia C. , Forget Frederic , Awada Ahmad , Canon Jean-Luc , Danso Michael , Lortholary Alain , Bourgeois Hugues , Tan-Chiu Elizabeth , Vincent Sylvie , Bahamon Brittany , Galinsky Kevin J. , Patel Chirag , Neuwirth Rachel , Leonard E. Jane , Diamond Jennifer R.
Published: April 2023

Supplementary Material containing Supplementary Methods, 5 Supplementary Figures, and 8 Supplementary Tables
Figure S2 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

Time-dependent metabolic clearances
Supplementary Tables 1-11 from Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
Authors: Johannet Paul , Coudray Nicolas , Donnelly Douglas M. , Jour George , Illa-Bochaca Irineu , Xia Yuhe , Johnson Douglas B. , Wheless Lee , Patrinely James R. , Nomikou Sofia , Rimm David L. , Pavlick Anna C. , Weber Jeffrey S. , Zhong Judy , Tsirigos Aristotelis , Osman Iman
Published: April 2023

Supplemental Table 1. Patient, slide, and tile distribution during the 5-fold cross validation for training the neural network on the NYU dataset. Supplemental Table 2. Odds Ratios (OR) and 95% Confidence Intervals (CI) from univariate analyses of baseline clinical and demographic variables. Supplemental Table 3. AUC for each of 5 independent test runs and the average AUC for both classifiers when applied to Vanderbilt slides scanned with the Aperio AT2. Supplemental Table 4. AUC for each of 5 independent test runs and the average AUC for both classifiers when applied to Vanderbilt slides scanned with the Leica SCN400. Supplemental Table 5. AUC with 95% confidence intervals for the DCNN and multivariable classifiers when applied exclusively to lymph node or soft tissue from the Vanderbilt dataset. Supplemental Table 6. Results of 3 independent test runs and the average performance of the DCNN classifier on slides from Vanderbilt scanned at 10x magnification. Shown are area under the curve (AUC) and 95% confidence intervals (CI). Supplemental Table 7. Hazard Ratios (HR) with 95% Confidence Intervals (CI) for the clinical variables used in the multivariable prediction model. Supplemental Table 8. AUC and 95% confidence intervals for the neural network prediction, ECOG performance status, treatment category, and each combination of the variables. Supplemental Table 9. Value importance of treatment category, baseline ECOG, and DCNN are reported as the absolute value of the Z-score. Supplemental Table 10. Confusion matrix for predictions of PFS on the cohort of Vanderbilt patients when slides were scanned with an Aperio AT2 scanner. Supplemental Table 11. Confusion matrix for predictions of PFS on the cohort of Vanderbilt patients when slides were scanned with a Leica SCN400 scanner.
Suppl Fig S3 from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Supplementary Figure S3. Change in PSA levels over time in patients with an ATM alteration (A), CDK12 alteration (B), CHEK2 alteration (C), or other DDR gene alteration (D). Patients with a PSA response are indicated with closed triangles; patients with a radiographic response are indicated with thicker lines. Abbreviation: PSA, prostate-specific antigen.
Suppl Fig S2C from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Supplementary Figure S2. Summary of observed alterations in CHEK2 (C).
Supplementary Figure S3 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S3. Tumor PMN-MDSC do not inhibit KIL effector function through PD-L1, arginase or NOS
Supplementary Figure S1 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S1. MOC2 tumors express myeloid chemokines
Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Authors: Armstrong Andrew J. , Nixon Andrew B. , Carmack Andrea , Yang Qian , Eisen Tim , Stadler Walter M. , Jones Robert J. , Garcia Jorge A. , Vaishampayan Ulka N. , Picus Joel , Hawkins Robert E. , Hainsworth John D. , Kollmannsberger Christian K. , Logan Theodore F. , Puzanov Igor , Pickering Lisa M. , Ryan Christopher W. , Protheroe Andrew , George Daniel J. , Halabi Susan
Published: April 2023

All supplementary data
Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Authors: Armstrong Andrew J. , Nixon Andrew B. , Carmack Andrea , Yang Qian , Eisen Tim , Stadler Walter M. , Jones Robert J. , Garcia Jorge A. , Vaishampayan Ulka N. , Picus Joel , Hawkins Robert E. , Hainsworth John D. , Kollmannsberger Christian K. , Logan Theodore F. , Puzanov Igor , Pickering Lisa M. , Ryan Christopher W. , Protheroe Andrew , George Daniel J. , Halabi Susan
Published: April 2023

Supplementary Figure 4A. Kaplan-Meier PFS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b1, VEGF-R1, HER-3, VEGF, PlGF, CD-73, VEGF-R3, and VEGF-R2
Supplementary Methods from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

File contains Supplementary Methods
Supplementary Figure 1 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Authors: Armstrong Andrew J. , Nixon Andrew B. , Carmack Andrea , Yang Qian , Eisen Tim , Stadler Walter M. , Jones Robert J. , Garcia Jorge A. , Vaishampayan Ulka N. , Picus Joel , Hawkins Robert E. , Hainsworth John D. , Kollmannsberger Christian K. , Logan Theodore F. , Puzanov Igor , Pickering Lisa M. , Ryan Christopher W. , Protheroe Andrew , George Daniel J. , Halabi Susan
Published: April 2023

CONSORT diagram
Supplementary Data from Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
Authors: Han Yoon-Chi , Kahler Jennifer , Piché-Nicholas Nicole , Hu Wenyue , Thibault Stephane , Jiang Fan , Leal Mauricio , Katragadda Madan , Maderna Andreas , Dushin Russell , Prashad Nadira , Charati Manoj B. , Clark Tracey , Tumey L. Nathan , Tan Xingzhi , Giannakou Andreas , Rosfjord Edward , Gerber Hans-Peter , Tchistiakova Lioudmila , Loganzo Frank , O'Donnell Christopher J. , Sapra Puja
Published: April 2023

Supplementary tables & figures
Supplementary Figure 3 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

Supplementary Figure 3 Evaluation of DLL3 expression in tumor types other than SCLC.
Supplementary Figure 1 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

Supplementary Figure 1 DLL3 is differentially expressed in SCLC tumors and cell lines compared with normal tissues.
Table S6 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S6
Supplemental Table 5 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

A description of the tumor biomarkers.
Table S4 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S4
Supplemental Table 3 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

Table summarizes the treatment-emergent adverse events considered related to study treatment.
Table S3 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S3
Table S2 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S2
Supplemental Figure 3 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

CD8 positive cells in tumors at baseline and post-treatment
Supplemental Figure 2 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

The study consort diagram.
Supplemental Figure 1 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

The generation of the screening ADA signal and confirmatory inhibition by the affinity-capture elution-bridge assay format.
Supplementary Figures from Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials
Authors: Upadhyaya Santhosh A. , Robinson Giles W. , Onar-Thomas Arzu , Orr Brent A. , Johann Pascal , Wu Gang , Billups Catherine A. , Tatevossian Ruth G. , Dhanda Sandeep Kumar , Srinivasan Ashok , Broniscer Alberto , Qaddoumi Ibrahim , Vinitsky Anna , Armstrong Gregory T. , Bendel Anne E. , Hassall Tim , Partap Sonia , Fisher Paul G. , Crawford John R. , Chintagumpala Murali , Bouffet Eric , Gururangan Sridharan , Mostafavi Roya , Sanders Robert P. , Klimo Paul , Patay Zoltan , Indelicato Daniel J. , Nichols Kim E. , Boop Frederick A. , Merchant Thomas E. , Kool Marcel , Ellison David W. , Gajjar Amar
Published: April 2023

Supplementary Figures S1 to S5
Supplementary Figure 1 from Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Authors: Clifton G. Travis , Hale Diane , Vreeland Timothy J. , Hickerson Annelies T. , Litton Jennifer K. , Alatrash Gheath , Murthy Rashmi K. , Qiao Na , Philips Anne V. , Lukas Jason J. , Holmes Jarrod P. , Peoples George E. , Mittendorf Elizabeth A.
Published: April 2023

The toxicity profiles were similar between the treatment arms. (A) There was no difference in the total number of graded adverse events (AE) between arms of the trial. (B) There was no significant difference in the maximum local and systemic toxicity experienced by each patient between arms of the trial.
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Figure 3. Tumor Tissue Analysis and Analysis of plasma TERT in Copies/mL.
Figures S1-S6 from Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
Authors: Lin Jessica J. , Choudhury Noura J. , Yoda Satoshi , Zhu Viola W. , Johnson Ted W. , Sakhtemani Ramin , Dagogo-Jack Ibiayi , Digumarthy Subba R. , Lee Charlotte , Do Andrew , Peterson Jennifer , Prutisto-Chang Kylie , Malik Wafa , Hubbeling Harper G. , Langenbucher Adam , Schoenfeld Adam J. , Falcon Christina J. , Temel Jennifer S. , Sequist Lecia V. , Yeap Beow Y. , Lennerz Jochen K. , Shaw Alice T. , Lawrence Michael S. , Ou Sai-Hong Ignatius , Hata Aaron N. , Drilon Alexander , Gainor Justin F.
Published: April 2023

Supplementary Figures
Supplementary Methods from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Authors: Schoenfeld Adam J. , Chan Joseph M. , Kubota Daisuke , Sato Hiroki , Rizvi Hira , Daneshbod Yahya , Chang Jason C. , Paik Paul K. , Offin Michael , Arcila Maria E. , Davare Monika A. , Shinde Ujwal , Pe'er Dana , Rekhtman Natasha , Kris Mark G. , Somwar Romel , Riely Gregory J. , Ladanyi Marc , Yu Helena A.
Published: April 2023

Supplementary Methods